New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
08:49 EDTFB, AAPL, TWTR, BBRY, TGT, NVS, GIS, SSNLF, T, BAC, ACT, IDCC, BX, AIG, NFLX, QCOMOn the Fly: Periodicals Wrap
WSJ: AT&T (T) discloses national security requests for thousands of accounts...China acknowledges anti-monopoly probe of Qualcomm (QCOM), InterDigital (IDCC)...Samsung (SSNLF) sees mix of hardware, software for distribution platform...Netflix (NFLX) faces video slowdown as broadband fee issues debated...Actavis (ACT) expected to seek more deals...REUTERS: General Mills (GIS) seeks deals in fast growing emerging markets...AIG (AIG) accused of holding BofA (BAC) $8.5B settlement 'hostage'...Novartis (NVS) Tokyo unit raided by prosecutors...BLOOMBERG: Blackstone (BX) acquires minority stake in Senator Investment Group...BlackBerry (BBRY) CEO blasts T-Mobile for pushing change to iPhones (AAPL)...OTHER NEWS: Banks' cost for Target (TGT) data breach over $200M, AP reports...Twitter (TWTR) could look to follow Facebook (FB) as app distribution platform, Re/code reports.
News For T;QCOM;IDCC;SSNLF;NFLX;ACT;GIS;AIG;BAC;NVS;BX;BBRY;AAPL;TGT;TWTR;FB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | all recent news | >>
December 8, 2014
13:38 EDTTWTRTwitter breaks to lows of the day, levels to watch
The shares are down over 6.7% to $35.89 at time of writing. Resistance is now at former support at $36.38. Support is now at $35.06.
13:16 EDTAAPLApple trades off session lows, levels to watch
Subscribe for More Information
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
12:25 EDTACTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTNVS, ACTLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
11:29 EDTNFLXNetflix falls to session lows, levels to watch
The shares are down over 2% to $342.44. At that price next support is at $340.05. Resistance is at $345.45.
11:21 EDTTWTRTwitter volatility low as shares pullback to four-month low
Twitter December weekly call option implied volatility is at 51, December is at 46, January at 43; compared to its 26-week average of 54 according to Track Data, suggesting decreasing price movement
10:16 EDTTWTRTwitter falls to session lows, levels to watch
Subscribe for More Information
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:05 EDTBXHudson Pacific to acquire EOP portfolio from Blackstone for $3.5B
Subscribe for More Information
07:31 EDTQCOMQualcomm announces collabration with vitaphone e-health solutions
Subscribe for More Information
07:24 EDTBXBlackstone to sell $3.5B of California properties to Hudson Pacific, WSJ says
Subscribe for More Information
06:37 EDTAAPLApple rumored to be launching 4-inch iPhone in 2015, Times of India reports
Apple is rumored to be developing a new iPhone with a 4-inch display, The Times of India reports, citing a report from The Electronic Times of Taiwan. According to supply chain sources, the device will launch in 2H15. Reference Link
06:35 EDTBACValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:22 EDTAAPLApple price target raised to $135 from $120 at Citigroup
Citigroup raised its earnings estimates for Apple after its field work indicated consumers are increasingly buying the higher memory iPhone 6 and 6+. Citi expects purchasing trends towards higher memory devices to drive stronger sales and margins. It believes consensus estimates are yet to factor in this development. The firm raised its price target for Apple shares to $135 from $120 and keeps a Buy rating on the name. Shares of phone maker closed Friday down 49c to $115.
06:15 EDTBXBlackstone implied volatility of 21 at lower end of index mean range
06:15 EDTSSNLF, AAPLLenovo shipments expected to lead Samsung by 9M in 2015, DigiTimes reports
Lenovo (LNVGY) is estimated to beat Samsung (SSNLF) in mobile device shipments in 2015 by about 9M units, reports DigiTimes Research. Lenovo is set to beat Samsung by about 1M units in 2014 and become the second largest mobile computing device brand vendor worldwide behind Apple (AAPL). DigiTimes Research says Lenovo and Samsung plan to focus on maintaining tablet shipments as demand weakens in 2015. Reference Link
06:00 EDTTWTRTwitter's former head of product leaving company, Re/code reports
Daniel Graf, who was replaced by Kevin Weil as head of product last month, is leaving the company, Re/code reports. Reference Link
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use